Desmond Curran, PhD

Director of Value Evidence
GSK

Disclosure: GSK (Individual(s) Involved: Self): Employee, Shareholder

Presentation(s):

• 5 - How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies

  Oral Abstract

• 7 - Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?

  Oral Abstract